Golden Helix Releases Discounted Pricing for Select Packages

We have been approached by a number of labs not working with COVID-19 but are also requiring financial assistance during these times. With this in mind, we are now offering three of our most popular software packages with significant discounts and extended 18-month licenses.

Featured in Clinical Lab Manager: Leveraging Next-Generation Sequencing Technology in the Fight Against COVID-19
By Andreas Scherer, PhD
President & CEO

It is an honor to be featured by Clinical Lab Manager where I discuss how Next-Gen Sequencing can be leveraged in the fight against COVID-19. If you are interested in reading this article, you can access it directly on the Clinical Lab Manager blog here.

Clinical Variant Analysis for Cancer eBook – Second Edition
By Andreas Scherer, PhD
President & CEO

This morning I released a new version of my eBook “Clinical Variant Analysis for Cancer – Second Edition.” The clinical utilization of Next-Generation Sequencing data to diagnose cancer has taken off, resulting in the need to standardize the interpretation and reporting of observed genomic variations. This eBook explores the entire clinical diagnostic process. It demonstrates how Golden Helix software can support clinicians with their decision making in concordance with the guidelines issued by the College of American Pathologists (AMP)... Read More

Genome Wide Association Tests and Mixed Linear Models in SVS
By Julia Love
Field Application Scientist

SVS offers several options to conduct genome wide association tests and mixed linear models. At times, it can be challenging to decide which test, model, or adjustments to use when setting up your analysis. I want to briefly explore the options available in SVS for association tests, and mixed linear models to hopefully facilitate in understanding and choosing which options... Read More

Auto-Updating Template Sources
By Aidan Bickford
Software Engineer

In VarSeq 2.2.1, you can set template annotation sources to automatically update to the latest version. Previously, VarSeq templates were frozen in time. Now, each new project created from a template would use the same source that was used when the template was created. When you save a template, you can have the sources automatically update to the latest version... Read More

CEO Corner

We have been heavily focused on supporting our community as we all continue to deal with the outcomes of COVID-19 across the globe. We began our efforts by issuing remote licenses for current customers and giving special considerations for organizations requiring financial assistance due to the current circumstances. We recently extended the scope of our relief programs which can be found on our site here outlining how we will continue to support our community throughout this quarter. Having that said, we are also continuing to focus on key topics like VSClinical. I just released a new eBook on our cancer workflow and major improvements which you can download here, and can expect more from us on this topic in the fall! Hope you all enjoy the start to your summer while staying safe and healthy.

Upcoming Webcast

Evaluating Oncogenicity in VSClinical

June 10, 2020 | 12:00 PM Eastern

Before accessing the clinical significance of a somatic mutation, one must determine if the mutation is likely to be a driver mutation (i.e. a mutation that provides a selective growth advantage, thereby promoting cancer development). To aid clinicians in this process, VSClinical provides an oncogenicity scoring system, which uses a variety of metrics to classify a given somatic mutation into one of the following categories: oncogenic, likely oncogenic, benign, likely benign, or uncertain significance.

Customer Success

Congratulations to all of our customers who have published this month! To highlight just a few:

"Frequency of Pathogenic/Likely Pathogenic Germline Variants in Cancer-related Genes Among Children with Acute Leukemia in Saudi Arabia" - Abdulrahman Alsultan & Colleagues, King Saud University / Published in Social Science & Medicine - Pediatric Blood & Cancer

"A Genome-wide Association Study for Resistance to the Insect Pest Leptocybe invasa in Eucalyptus grandis Reveals Genomic Regions and Positional Candidate Defence Genes" - Zander Myburg, Marja O’Neill, Sanushka Naidoo & Colleagues, University of Pretoria / Published in Plant & Cell Physiology

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.